Home / Stock ratings / Healthcare Stocks / ABT
Stock rating · Pharmaceutical Preparations
Abbott Laboratories (ABT) Stock Rating & Analysis
As of October 6, 2026, MELANY rates Abbott Laboratories 60 out of 100 (Hold). Its highest factor score is risk-adjusted profile at 75, and its lowest is macro fit at 50.
MELANY ratingRated 2026-10-06ABT · composite score
About Abbott Laboratories
Abbott manufactures and markets cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Its products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, adult nutritional liquids, continuous glucose monitors, and immunoassays and point-of-care diagnostic equipment, and it derives roughly 60% of sales outside the United States.
Rating as of 2026-10-06 · this is a dated snapshot; the live rating is in the app (Pro, free for 30 days). The price above updates in real time.
Why ABT scores 60/100
ABT's 8 factor scores run from 50 to 75, and 3 of them sit above its composite of 60. Here is how ABT breaks down.
Whether the price looks cheap or expensive against earnings, growth, and peers.
- Forward P/E 16.2x, earnings growth accelerating
Margins, returns on capital, and balance-sheet strength.
- Gross margin 57%
Direction and relative strength of the recent share-price trend.
History of beating or missing estimates, and where estimates are heading.
What Wall Street price targets and revisions are signalling.
Near-term events that could move the stock.
Upside weighed against volatility and drawdown risk.
How the current rate and market regime suits this kind of company.
How ABT compares
As of October 7, 2026, Abbott Laboratories is tied for 19th of 20 in Healthcare Stocks, where the average score is 67.
Key risks for ABT
- No specific company-level red flags detected, monitor macro regime changes
Sector and theme context
Abbott Laboratories sits in the Healthcare sector theme, which MELANY currently rates 37/100 for strength. Theme strength feeds ABT's momentum and catalyst factors above.
Tracking ABT
Abbott Laboratories rates Hold right now, so MELANY is not flagging a fresh entry. Add ABT to a watchlist in the app to follow its rating; an alert the moment it changes is part of Pro, free for 30 days.
How MELANY rates ABT
MELANY is a rules-based engine that scores every stock from 0 to 100 across eight weighted factors, then re-scores as new price, earnings, and fundamental data arrive. Abbott Laboratories's 60/100 reflects mature factor weighting for its profile.
Ratings are algorithmic and change with the data. They are research and education, not personalized investment advice.
Frequently asked questions about ABT
Is Abbott Laboratories (ABT) a buy?
As of 2026-10-06, MELANY rated Abbott Laboratories Hold with a composite score of 60/100. That is a dated snapshot, not the live rating, and it is an algorithmic reading built from eight factors rather than personalized investment advice. Review the factor breakdown above and the disclaimer below before making any decision.
What is Abbott Laboratories's MELANY score?
Abbott Laboratories (ABT) has a MELANY composite score of 60/100, combining valuation, business quality, price momentum, earnings track record, analyst sentiment, catalyst setup, risk-adjusted profile, macro fit.
How is the ABT stock rating calculated?
MELANY scores ABT from 0 to 100 across eight weighted factors using live market and fundamental data, then refreshes the rating automatically as new data arrives.
Should I buy Abbott Laboratories stock?
That decision is yours; Market Eyes Live does not give buy or sell advice. What the data says: MELANY rates Abbott Laboratories (ABT) Hold with a composite of 60/100 as of 2026-10-06. The factor breakdown above shows what is driving that, which is a better basis for a decision than any one-word verdict.
What is the ABT stock price forecast?
MELANY does not publish price targets or forecasts for ABT. Predicting a future price is exactly the kind of false precision the confidence framework avoids. Instead it scores today's setup, 60/100 across eight factors for Abbott Laboratories, and re-scores automatically as new price, earnings, and fundamental data arrive.
Is ABT stock overvalued or undervalued?
MELANY's valuation factor currently reads 58/100 for Abbott Laboratories, where a higher score means the price looks more attractive on that measure. Scores in the 70s and above read as attractively priced, the mid range as roughly fair, and low scores as stretched. The factor breakdown above shows what drives ABT's read.
What price should I buy ABT at?
MELANY is not flagging a fresh entry for ABT at its current Hold rating, so there is no entry zone to publish right now. Add ABT to a watchlist in the app to follow it; an alert the moment the rating changes is part of Pro, free for 30 days.
What are the risks of buying ABT stock?
The top risks MELANY currently flags for Abbott Laboratories: No specific company-level red flags detected, monitor macro regime changes. The rating on this page already weighs these against the bullish factors; see the risk-adjusted profile score in the breakdown above.
Is Abbott Laboratories a good long-term investment?
For long-term durability the two factors that matter most are business quality, which MELANY scores 59/100 for Abbott Laboratories, and earnings track record, at 51/100. The 60/100 composite blends those with six shorter-horizon factors. Durable quality at a fair price is the long-term case to test; this is research, not personalized investment advice.
Will ABT stock go up?
Nobody can promise a stock's direction, and Market Eyes Live does not predict prices. The measurable part: MELANY's price momentum factor reads 51/100 for ABT right now, and the catalyst setup factor tracks whether near-term events could move it. Both re-score automatically as the data changes.
How current is this ABT rating?
The rating on this page is a snapshot of MELANY's read as of 2026-10-06. The price shown updates live, but the score is not recomputed on this page. MELANY re-scores ABT continuously as new price, earnings, and fundamental data arrive, and the current rating is in the app (Pro, free for 30 days).
How this rating works
Market Eyes Live
Every rating graded in public, ABT included
MELANY scores more than 11,000 U.S. stocks and ETFs, PRISM ranks conviction and APEX writes the plan with one entry zone. Free to start on iOS and the web.